Atlanta, GA – Scibility Media – 11/10/2014.
This article discusses two companies: Radius Health Inc(NASDAQ:RDUS) and Autobytel Inc.(NASDAQ:ABTL)
Radius Health Inc(NASDAQ:RDUS) is a Massachusetts-based biopharmaceutical company that develops novel therapeutics for patients with serious endocrine-mediated diseases, including osteoporosis. The company’s lead product, BA058, is a novel synthetic peptide analog is in Phase III clinical development for the treatment of osteoporosis.
On Nov. 3rd, the company announced that it had appointed Dr. William H. Dere to its board of directors. Previously, Dere had lead the development program of Prolia at Amgen. He is also the Executive Director of Personalized Health at the University of Utah Health Services Center.
This past week, Radius Health also presented at the BIO-Europe Conference in Frankfort, Germany. The company’s Vice President of Business Development & Strategy, Geoffrey A. Swire, represented Radius Health.
Autobytel Inc.(NASDAQ:ABTL) reported its third quarter financial results. The company announced that its total revenues had increased from third quarter 2013’s mark of $21.6 million to a figure of $27.4 million.
The California-based Internet Information Provider, which operates as an automotive marketing services company, assists automotive retail dealers and manufacturers as they market and sell new vehicles. Autobytel uses online lead referrals, dealer marketing products and services, and online advertising programs.
The company has traded within a range of $7.82 to $18.82 over the past 52 weeks, yet finished yesterday’s trading at a closing price of $9.90. This figure suggests that Autobytel’s trading price is on the decline.
EquiPress.com is a non-advertisement based network (currently in limited release) designed for investors to discover and communicate with publicly traded companies in real-time.
Sign-up for free now to experience the full benefits of EquiPress pre-launch.
Discover and communicate with companies you would otherwise never have seen based on your interests, company news, personalized news feeds, and one-on-one communications with no middle-men nor advertisements. Read our no advertisements pledge.
Can’t find your company on EquiPress? Send us an email to firstname.lastname@example.org and we will contact them for you.
Interested in a one month free trial? Get access to our private investor network, real-time news distribution, automatic disclaimers, corporate analytics, verified public profile, and industry-wide marketing of your corporate news.
Disclosure: EquiPress is not a registered investment adviser and nothing contained in any materials should be construed as a recommendation to buy or sell securities. EquiPress does not hold any equity or financial interest in any publicly traded company. EquiPress provides a uniform subscription based service to all publicly traded companies on a monthly basis at a rate of $495 to provide investor awareness. EquiPress receives only cash compensation from clients. Despite the relationship, EquiPress maintains a neutral stance (nonbiased) on any investment related opinions and exists solely for the purpose of allowing investors to communicate with the publicly traded companies in an effort to establish for themselves investment considerations. Investors should always conduct their own due diligence with any potential investment. Always seek help from a professional financial advisor. Please visit www.equipress.com for complete risks and disclosures.